More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
Open Access
- 16 September 2024
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (18) , 4913-4923
Abstract
Treatment with direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) is effective and safe. However, bleeding complications still occur. Whether DOAC level measurement may further improve treatment efficacy and safety is still an open issue. In the "Measure and See" study, venous blood was collected 15-30 days after DOAC initiation in patients with AF who were then followed up for 1 year to record the occurrence of major and clinically relevant nonmajor bleeding. DOAC plasma levels were measured in 1 laboratory, and results were kept blind to patients and treating doctors. Trough DOAC levels were assessed in 1657 patients (957 [57.7%] and 700 patients treated with standard and low-dose, respectively). Fifty bleeding events were recorded during 1606 years of follow-up (3.11% pt/yrs). Fifteen bleeding events (4.97% pt/yrs) occurred in patients with C-trough standardized values in the highest activity class (>0.50), whereas 35 events (2.69% pt/yrs) occurred in those with values in the 2 lower classes (≤0.50, P = .0401). Increasing DOAC levels and low-dose DOAC use were associated with increased bleeding risk in the first 3 months of treatment. Overall, 19% of patients receiving low doses had standardized values in the highest class. More bleeding occurred in patients on low (4.3% pt/yrs) vs standard (2.2% pt/yrs; P = .0160) dose DOAC. Early measurement of DOAC levels in patients with AF identified many individuals with high levels despite the low doses use and had more bleeding risk during the first 3 months of treatment. This trial was registered at www.ClinicalTrials.gov as #NCT03803579.Keywords
This publication has 33 references indexed in Scilit:
- Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative ReviewClinical Pharmacokinetics, 2023
- 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral AnticoagulantsThrombosis and Haemostasis, 2021
- Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral AnticoagulantsJACC, 2020
- Preanalytical Variables in Coagulation Testing: Setting the Stage for Accurate ResultsSeminars in Thrombosis and Hemostasis, 2019
- Edoxaban plasma levels in patients with non-valvular atrial fibrillation: Inter and intra-individual variability, correlation with coagulation screening test and renal functionThrombosis Research, 2019
- Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assayThrombosis Research, 2017
- Appropriate Apixaban DosingJAMA Cardiology, 2016
- Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinicsThrombosis Research, 2016
- Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor XaClinical Pharmacokinetics, 2015
- Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)The Lancet, 1996